1
|
Szyszkowska A, Olesiewicz T, Płońska-Korabiewska I, Tarasiuk E, Olesiewicz B, Knapp M, Śledziewski R, Sobkowicz B, Lisowska A. The Importance of Lung Ultrasound and IGFBP7 (Insulin-like Growth Factor Binding Protein 7) Assessment in Diagnosing Patients with Heart Failure. J Clin Med 2024; 13:2220. [PMID: 38673493 PMCID: PMC11051327 DOI: 10.3390/jcm13082220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Revised: 03/30/2024] [Accepted: 04/09/2024] [Indexed: 04/28/2024] Open
Abstract
Background: In daily practice, there are problems with adequately diagnosing the cause of dyspnea in patients with heart failure with preserved and mildly reduced ejection fractions (HFpEF and HFmrEF). This study aimed to assess the usefulness of lung ultrasound in diagnosing HFpEF and HFmrEF and determine its correlation with IGFBP7 (insulin-like growth factor binding protein 7), NTproBNP (N-terminal pro-B-type natriuretic peptide), and echocardiographic markers. Methods: The research was conducted on 143 patients hospitalized between 2018 and 2020, admitted due to dyspnea, and diagnosed with HFpEF and HFmrEF. Venous blood was collected from all participants to obtain basic biochemical parameters, NTproBNP, and IGFBP7. Moreover, all participants underwent echocardiography and transthoracic lung ultrasound. Two years after hospitalization a follow-up telephone visit was performed. Results: The number of B-lines in the LUS ≥ 16 was determined with a sensitivity of-73% and specificity of-62%, indicating exacerbation of heart failure symptoms on admission. The number of B-lines ≥ 14 on admission was determined as a cut-off point, indicating an increased risk of death during the 2-year follow-up period. The factors that significantly impacted mortality in the study patient population were age and the difference between the number of B-lines on ultrasound at admission and at hospital discharge. IGFBP7 levels had no significant effect on the duration of hospitalization, risk of rehospitalization, or mortality during follow-up. Conclusions: Lung ultrasonography provides additional diagnostic value in patients with HFpEF or HFmrEF and exacerbation of heart failure symptoms. The number of B-lines ≥ 14 may indicate an increased risk of death.
Collapse
Affiliation(s)
- Anna Szyszkowska
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (I.P.-K.); (E.T.); (M.K.); (B.S.)
| | - Tomasz Olesiewicz
- Department of Cardiology, Hospital in Ostrów Mazowiecka, 07-300 Ostrów Mazowiecka, Poland; (T.O.); (B.O.)
| | - Izabela Płońska-Korabiewska
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (I.P.-K.); (E.T.); (M.K.); (B.S.)
| | - Ewa Tarasiuk
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (I.P.-K.); (E.T.); (M.K.); (B.S.)
| | - Barbara Olesiewicz
- Department of Cardiology, Hospital in Ostrów Mazowiecka, 07-300 Ostrów Mazowiecka, Poland; (T.O.); (B.O.)
| | - Małgorzata Knapp
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (I.P.-K.); (E.T.); (M.K.); (B.S.)
| | - Rafał Śledziewski
- Department of Radiology, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Bożena Sobkowicz
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (I.P.-K.); (E.T.); (M.K.); (B.S.)
| | - Anna Lisowska
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (I.P.-K.); (E.T.); (M.K.); (B.S.)
| |
Collapse
|
2
|
Jędrysik M, Wyszomirski K, Różańska-Walędziak A, Grosicka-Maciąg E, Walędziak M, Chełstowska B. The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity. Biomedicines 2024; 12:159. [PMID: 38255264 PMCID: PMC10813748 DOI: 10.3390/biomedicines12010159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 12/29/2023] [Accepted: 01/10/2024] [Indexed: 01/24/2024] Open
Abstract
Metabolic illnesses, including obesity and type 2 diabetes, have become worldwide epidemics that have an effect on public health. Clinical investigations and further exploration of these mechanisms could lead to innovative, effective, and personalized treatment strategies for individuals. It is important to screen biomarkers in previous studies to discover what is missing. Glucagon-like peptide-1's role in insulin secretion and glucose control highlights its diagnostic and therapeutic potential. Glucose-dependent insulinotropic peptide's influence on postprandial satiety and weight management signifies its importance in understanding metabolic processes. Monocyte chemoattractant protein-1's involvement in inflammation and insulin resistance underlines its value as a diagnostic marker. Insulin-like growth factor-binding protein-7's association with insulin sensitivity and kidney function presents it as a potential target for these diseases' management. In validating these biomarkers, it will be easier to reflect pathophysiological processes, and clinicians will be able to better assess disease severity, monitor disease progression, and tailor treatment strategies. The purpose of the study was to elucidate the significance of identifying novel biomarkers for type 2 diabetes mellitus and obesity, which can revolutionize early detection, risk assessment, and personalized treatment strategies. Standard literature searches of PubMed (MEDLINE), EMBASE, and Cochrane Library were conducted in the year 2023 to identify both original RCTs and recent systematic reviews that have explored the importance of identifying novel biomarkers for T2D and obesity. This search produced 1964 results, and then was reduced to randomized controlled trial and systematic reviews, producing 145 results and 44 results, respectively. Researchers have discovered potential associations between type 2 diabetes mellitus and obesity and the biomarkers glucagon-like peptide-1, glucose-dependent insulinotropic peptide, monocyte chemoattractant protein-1, and insulin-like growth factor-binding protein-7. Understanding the role of those biomarkers in disease pathogenesis offers hope for improving diagnostics, personalized treatment, and prevention strategies.
Collapse
Affiliation(s)
- Malwina Jędrysik
- Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland; (M.J.); (E.G.-M.); (B.C.)
| | - Krzysztof Wyszomirski
- Department of Human Physiology and Pathophysiology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland;
| | - Anna Różańska-Walędziak
- Department of Human Physiology and Pathophysiology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland;
| | - Emilia Grosicka-Maciąg
- Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland; (M.J.); (E.G.-M.); (B.C.)
| | - Maciej Walędziak
- Department of General, Oncological, Metabolic and Thoracic Surgery, Military Institute of Medicine—National Research Institute, Szaserów 128 St., 04-141 Warsaw, Poland;
| | - Beata Chełstowska
- Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland; (M.J.); (E.G.-M.); (B.C.)
| |
Collapse
|
3
|
Szyszkowska A, Barańska S, Sawicki R, Tarasiuk E, Dubatówka M, Kondraciuk M, Sawicka-Śmiarowska E, Knapp M, Głowiński J, Kamiński K, Lisowska A. Insulin-Like Growth Factor-Binding Protein 7 (IGFBP-7)-New Diagnostic and Prognostic Marker in Symptomatic Peripheral Arterial Disease?-Pilot Study. Biomolecules 2022; 12:712. [PMID: 35625639 PMCID: PMC9138972 DOI: 10.3390/biom12050712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 05/05/2022] [Accepted: 05/12/2022] [Indexed: 11/18/2022] Open
Abstract
The aim of our study was to evaluate the importance of insulin-like growth-factor-binding protein 7 (IGFBP-7) as a potential marker of symptomatic peripheral artery disease (PAD) occurrence. The study group consisted of 145 patients with diagnosed PAD, who qualified for the invasive treatment. The control group consisted of 67 individuals representing the local population and an ischemic heart disease (IHD) group of 88 patients after myocardial infarction or percutaneous coronary intervention. Patients with PAD had significantly higher IGFBP-7 concentrations than control group (1.80 ± 1.62 vs. 1.41 ± 0.45 ng/mL, p = 0.04). No significant differences between PAD patients and IHD patients were found (1.80 ± 1.62 vs. 1.76 ± 1.04 ng/mL, p = 0.783). Patients with multilevel PAD presented significantly higher IGFBP-7 concentrations than patients with aortoiliac PAD-median 1.18 (IQR 0.48-2.23) vs. 1.42 ng/mL (0.71-2.63), p = 0.035. In the group of patients who died or had a major adverse cardiovascular event (MACE) during six months of follow-up, a statistically significant higher IGFBP-7 concentration was found (median 2.66 (IQR 1.80-4.93) vs. 1.36 ng/mL (IQR 0.65-2.34), p = 0.004). It seems that IGFBP-7 is elevated in patients with atherosclerotic lesions-regardless of their locations. Further research should be conducted to verify IGFBP-7 usefulness as a predictor of MACE or death.
Collapse
Affiliation(s)
- Anna Szyszkowska
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (R.S.); (E.T.); (E.S.-Ś.); (M.K.); (K.K.)
| | - Sylwia Barańska
- Department of Vascular Surgery and Transplantation, Medical University of Bialystok, 15-276 Bialystok, Poland; (S.B.); (J.G.)
| | - Robert Sawicki
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (R.S.); (E.T.); (E.S.-Ś.); (M.K.); (K.K.)
| | - Ewa Tarasiuk
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (R.S.); (E.T.); (E.S.-Ś.); (M.K.); (K.K.)
| | - Marlena Dubatówka
- Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, 15-276 Bialystok, Poland; (M.D.); (M.K.)
| | - Marcin Kondraciuk
- Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, 15-276 Bialystok, Poland; (M.D.); (M.K.)
| | - Emilia Sawicka-Śmiarowska
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (R.S.); (E.T.); (E.S.-Ś.); (M.K.); (K.K.)
| | - Małgorzata Knapp
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (R.S.); (E.T.); (E.S.-Ś.); (M.K.); (K.K.)
| | - Jerzy Głowiński
- Department of Vascular Surgery and Transplantation, Medical University of Bialystok, 15-276 Bialystok, Poland; (S.B.); (J.G.)
| | - Karol Kamiński
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (R.S.); (E.T.); (E.S.-Ś.); (M.K.); (K.K.)
- Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, 15-276 Bialystok, Poland; (M.D.); (M.K.)
| | - Anna Lisowska
- Department of Cardiology, Medical University of Bialystok, 15-276 Bialystok, Poland; (A.S.); (R.S.); (E.T.); (E.S.-Ś.); (M.K.); (K.K.)
| |
Collapse
|
4
|
IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart Disease. Biomolecules 2022; 12:biom12020274. [PMID: 35204773 PMCID: PMC8961623 DOI: 10.3390/biom12020274] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 01/27/2022] [Accepted: 02/01/2022] [Indexed: 02/01/2023] Open
Abstract
The objective of this study was to determine the associations between insulin-like growth-factor-binding protein 7(IGFBP7) concentrations and concentrations of troponin T(TnT), N-terminal pro-B-type natriuretic peptide(NT-proBNP) and the parameters of kidney function in patients with stable ischemic heart disease(IHD). The IHD group consisted of 88 patients, and the population group comprised 66 subjects without a history of IHD. IGFBP7, TnT and NTproBNP concentrations were measured. The IGFBP7 value was considerably higher in the IHD group (1.76 ± 1 ng/mL vs. 1.43 ± 0.44 ng/mL, respectively, p = 0.019). Additionally, IHD subjects had a significantly higher concentration of TnT and NTproBNP. In both groups there was a significant correlation between IGFBP7 and serum parameters of kidney function (creatinine concentration: population gr. r = 0.45, p < 0.001, IHD gr. r = 0.86, p < 0.0001; urea concentration: population gr. r = 0.51, p < 0.0001, IHD gr. r = 0.71, p < 0.00001). No correlation between IGFBP7 and microalbuminuria or the albumin to creatinine ratio in urine was found. Moreover, there was a significant correlation between IGFBP7 concentration and markers of heart injury/overload-TnT and NT-BNP(r = 0.76, p < 0.001 and r = 0.72, p < 0.001, respectively). Multivariate regression analysis in joint both revealed that the IGFBP7 concentration is independently associated with urea, creatinine and TnT concentrations (R2 for the model 0.76). IHD patients presented significantly higher IGFBP7 concentrations than the population group. Elevated IGFBP7 levels are associated predominantly with markers of kidney function and myocardial damage or overload.
Collapse
|